Gene:
GYS1
glycogen synthase 1 (muscle)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  GSY
PharmGKB Accession Id: PA29084

Details

Cytogenetic Location: chr19 : q13.33 - q13.33
GP mRNA Boundary: chr19 : 49471382 - 49496610
GP Gene Boundary: chr19 : 49468382 - 49506610
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to GYS1: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clinica chimica acta; international journal of clinical chemistry. 2009. RuaƱo Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. The New England journal of medicine. 2007. Kollberg Gittan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality. PloS one. 2007. Fredriksson Jenny, et al. PubMed

LinkOuts

UniProtKB:
GYS1_HUMAN (P13807)
Q9BTT9_HUMAN (Q9BTT9)
Ensembl:
ENSG00000104812
GenAtlas:
GYS1
GeneCard:
GYS1
MutDB:
GYS1
ALFRED:
LO104447U
HuGE:
GYS1
Comparative Toxicogenomics Database:
2997
ModBase:
P13807
HumanCyc Gene:
HS02622
HGNC:
4706

Common Searches